Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia-A Retrospective Study.
Daniel ChoberBogusz Jan Aksak-WąsJolanta Niścigorska-OlsenMałgorzata NiekraszMiłosz ParczewskiPublished in: Biomedicines (2022)
In patients with COVID-19 pneumonia with at least moderate lung involvement, CRS and acute pulmonary embolism, administration of TCZ is associated with increased mortality. Therefore, TCZ should be used with caution in SARS-CoV-2 cases with pulmonary embolism.
Keyphrases
- pulmonary embolism
- sars cov
- respiratory failure
- inferior vena cava
- respiratory syndrome coronavirus
- coronavirus disease
- rheumatoid arthritis
- liver failure
- cardiovascular events
- high intensity
- drug induced
- risk factors
- community acquired pneumonia
- cardiovascular disease
- rheumatoid arthritis patients
- intensive care unit
- mechanical ventilation
- aortic dissection